logo
Volkswagen has a plan to turn things around

Volkswagen has a plan to turn things around

Yahoo17-02-2025

There's no denying that Volkswagen has been on a downward trend over the past few years, and now the automaker themselves recognizes that fact. With that recognition comes pieces put in place to fix the problem. Volkswagen has a plan to catch up to competitors, and it all starts in Wolfsburg, Germany.Chinese competitors and electrification have put Volkswagen between a rock and a hard place. In order to catch up to the competition, Volkswagen has a strategy they're calling Triple A, which stands for Accelerate, Attack, and Achieve.
In order to catch up to the competition, Volkswagen plans to put nine new models on the road by 2027. So far, VW has confirmed two smaller, more affordable models will join the ID. family, namely the ID.2, expected to arrive in 2026, and the ID.1, expected in 2027.
Volkswagen plans to unveil the new ID.1 at the beginning of March. The upcoming model will feature an all-electric powertrain and start at around €20,000, or roughly $20,900 USD. Employees at the Wolfsburg plant will see the upcoming model before the general public.
'An affordable, high-quality, and profitable electric Volkswagen from Europe for Europe – that's the Champions League of automotive engineering!' said Thomas Schäfer, CEO of VW Passenger Cars.
The Wolfsburg plant will remain the main stage for Volkswagen's electrification plans. In order to make way for new technology to produce electric models, Volkswagen is moving production of the Golf to Mexico.
The upcoming all-electric Golf, however, will be built in Wolfsburg with help from Rivian. It's expected to return towards the end of the decade, marking the model's comeback after VW ended production of the original e-Golf back in December 2020.As it currently stands, Volkswagen certainly isn't in a bad spot. The German automaker has the ID. family in their pocket, which has been one of the automaker's best-selling models. Since the ID. brand hit the market in 2019, more than 1.35 million models have left dealer lots under new ownership, just over a quarter of which were the ID.3. Last year, the VW ID.3 sold 383,100 EVs globally.
Currently, Volkswagen only offers the ID.4 and ID. Buzz in the United States. Given how much Americans love their larger vehicles, it's not a bad offering by any means. Unfortunately, the ID. Buzz was met with a lukewarm reception, largely due to its price. On the bright side, Volkswagen is expected to bring the ID.8, an all-electric three-row SUV, to the United States in the next few years.
Volkswagen also offers more all-electric models in Europe and other markets, including China. In 2024, just over 149,000 VW ID.3 models were sold, while the ID. Buzz sold just under 30,000 units. The VW ID.4, the standard SUV version, and ID.5, the coupe model, saw the best sales of VW's ID. family, coming in at 182,000 units.With the introduction of two smaller, more affordable all-electric models, Volkswagen is set to make inroads with a new demographic of consumers. On top of that, a larger all-electric three-row SUV will give American drivers another model to choose from.
Volkswagen is currently in phase one of its Triple-A strategy. With plenty of all-new EVs on the horizon, the German automaker is positioning itself to battle with Chinese automakers on a global scale in the near future.
While Volkswagen still has some catching up to do, the fact that it has not only avoided closing plants but is also setting them up for the future is a positive indicator. On the other hand, by the time its new EVs launch, the competition will be even fiercer. There's not much left to do but wait and see what the German automaker has in store.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Scottie Scheffler's Massive Earnings on PGA Tour Top Phil Mickelson
Scottie Scheffler's Massive Earnings on PGA Tour Top Phil Mickelson

Yahoo

time26 minutes ago

  • Yahoo

Scottie Scheffler's Massive Earnings on PGA Tour Top Phil Mickelson

Scottie Scheffler's Massive Earnings on PGA Tour Top Phil Mickelson originally appeared on Athlon Sports. Scottie Scheffler is rewriting history with every swing. Since May alone, he's bagged multiple wins, including a massive victory at the Memorial Tournament, where he pocketed $4 million. Advertisement Before that, he walked away with $3.42 million at the PGA Championship and $1.78 million at The CJ Cup Byron Nelson. With a strong T9 finish at the AT&T Pebble Beach Pro-Am, he added another $535,000 to his soaring total. Simply put, Scheffler has been unstoppable. In just the last 40 months, Scheffler has racked up more wins than Jordan Spieth has in his entire career. He's also secured more top-3 finishes than Jason Day and more top-10s than Max Homa. When it comes to major victories, he's already outpaced Dustin Johnson. But perhaps the most staggering stat of them all he's made more PGA Tour earnings than Phil Mickelson, and in a fraction of the time. Dublin, Ohio, USA; Scottie Scheffler addresses the crowd after winning the Memorial Tournament presented by Workday golf Doster-Imagn Images Scheffler's total PGA Tour earnings now stand at a jaw-dropping $133,293,567 and that doesn't even count any LIV Golf paydays. Advertisement In comparison, Phil Mickelson's PGA Tour earnings sit at $81,053,932. To surpass a Hall of Famer like Lefty in just over three years? That's elite company. The numbers don't lie. Scheffler isn't just winning he's dominating. And as Golf Digest highlighted, the 28-year-old is delivering at a pace that makes legends look over their shoulders. From consistent top finishes to his calm under pressure, it's no wonder fans are calling this a generational run. With his incredible streak and record-breaking earnings, Scottie Scheffler is proving that greatness isn't built over decades sometimes, it only takes 40 months. Advertisement Related: Scottie Scheffler News Emerges on Tuesday After Memorial Win This story was originally reported by Athlon Sports on Jun 7, 2025, where it first appeared.

Why Recursion Pharmaceuticals (RXRX) Soared On Friday
Why Recursion Pharmaceuticals (RXRX) Soared On Friday

Yahoo

timean hour ago

  • Yahoo

Why Recursion Pharmaceuticals (RXRX) Soared On Friday

We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Recursion Pharmaceuticals (RXRX) Soared On Friday
Why Recursion Pharmaceuticals (RXRX) Soared On Friday

Yahoo

time2 hours ago

  • Yahoo

Why Recursion Pharmaceuticals (RXRX) Soared On Friday

We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store